frα protein  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Sino Biological frα protein
    Frα Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/frα protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    frα protein - by Bioz Stars, 2023-03
    93/100 stars

    Images

    frα protein  (Sino Biological)


    Bioz Verified Symbol Sino Biological is a verified supplier
    Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Sino Biological frα protein
    Frα Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/frα protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    frα protein - by Bioz Stars, 2023-03
    93/100 stars

    Images

    frα protein  (Sino Biological)


    Bioz Verified Symbol Sino Biological is a verified supplier
    Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Sino Biological frα protein
    a – h Induction time courses of antigen-specific IFN- γ + T cell frequencies (T cells per million PBMCs, mean + s.e.m.) for <t>FRα</t> epitopes FR30, FR56, FR76, FR113, FR238 <t>FRα</t> <t>protein,</t> TT, and control cyclin D1 peptide, respectively, in 18 evaluable patients. i – p Induction phase time courses of antigen-specific IL-17 + T cell frequencies (T cells per million PBMCs, mean + s.e.m.) for the same antigens in the same patients. The first time point is prior to apheresis; the second following apheresis and prior to Cycle 1 of vaccine treatment, and the remainder following Cycles 1–5 of vaccine induction. Reddened symbols indicate p < 0.008 (Bonferroni corrected) significance by Wilcoxon matched pairs two-sided test, compared to the baseline value for that antigen. Exact P values are indicated in Supplementary Tables and .
    Frα Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/frα protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    frα protein - by Bioz Stars, 2023-03
    93/100 stars

    Images

    1) Product Images from "Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients"

    Article Title: Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

    Journal: Nature Communications

    doi: 10.1038/s41467-020-18962-z

    a – h Induction time courses of antigen-specific IFN- γ + T cell frequencies (T cells per million PBMCs, mean + s.e.m.) for FRα epitopes FR30, FR56, FR76, FR113, FR238 FRα protein, TT, and control cyclin D1 peptide, respectively, in 18 evaluable patients. i – p Induction phase time courses of antigen-specific IL-17 + T cell frequencies (T cells per million PBMCs, mean + s.e.m.) for the same antigens in the same patients. The first time point is prior to apheresis; the second following apheresis and prior to Cycle 1 of vaccine treatment, and the remainder following Cycles 1–5 of vaccine induction. Reddened symbols indicate p < 0.008 (Bonferroni corrected) significance by Wilcoxon matched pairs two-sided test, compared to the baseline value for that antigen. Exact P values are indicated in Supplementary Tables and .
    Figure Legend Snippet: a – h Induction time courses of antigen-specific IFN- γ + T cell frequencies (T cells per million PBMCs, mean + s.e.m.) for FRα epitopes FR30, FR56, FR76, FR113, FR238 FRα protein, TT, and control cyclin D1 peptide, respectively, in 18 evaluable patients. i – p Induction phase time courses of antigen-specific IL-17 + T cell frequencies (T cells per million PBMCs, mean + s.e.m.) for the same antigens in the same patients. The first time point is prior to apheresis; the second following apheresis and prior to Cycle 1 of vaccine treatment, and the remainder following Cycles 1–5 of vaccine induction. Reddened symbols indicate p < 0.008 (Bonferroni corrected) significance by Wilcoxon matched pairs two-sided test, compared to the baseline value for that antigen. Exact P values are indicated in Supplementary Tables and .

    Techniques Used:

    a , d The mean ( n = 18) pre-immunization (Pre) and highest post-vaccination (Post) frequency of antigen-specific IFN- γ + ( a ) or IL-17 + T ( d ) cell frequencies (per million PBMCs plated) that recognize the vaccine epitopes as well as the whole FRα protein. Post-vaccination samples included up to week 19. P values were calculated using the 2-sided test Wilcoxon matched pairs at a significance level of P ≤ 0.05. b , e The % of patients that responded to vaccine epitopes with IFN- γ + or IL-17 + T cell responses, respectively. c , f The distribution of IFN- γ + and IL-17 + T cell responses to the individual epitopes, respectively. g Correlation analysis heatmap comparing the magnitude of maximal peptide-specific IFN- γ + T cells to each other and to the maximal FRα protein-specific IFN- γ + T cell response. Inset values are Spearman’s Rho. h The same for IL-17 + T cell responses. All correlations ≥0.45 were P < 0.05 (Benjamini-Hochberg adjusted two-sided test, exact P values are indicated in Supplementary Tables and ). i Correlation plot between the protein-specific IFN- γ + T cell response and the IL-17 analyses between the highest FRα protein-specific IFN- γ + and highest FRα protein-specific IL-17 + T cells. j Correlation analysis between the number of peptides to which IFN- γ + T cells were generated and the number of peptides to which IL-17 + T cells were generated. k Correlation plots between the vaccine IFN- γ score (The sum of the individual patient T cell response to the epitopes) and tumor FRα expression. Inset values for ( i – k ) are Spearman’s Rho coefficient ( r ) and P value. l Correlation plots between the vaccine Th17 score (The sum of the individual patient T cell response to the epitopes) and tumor FRα expression. Inset values are Pearson’s Rho coefficient (r) and P value. Each symbol in ( i – l ) represents a unique patient ( n = 18 for each panel). In some cases the symbols overlap obscuring each other. Inset best-fit lines were calculated with non-linear least squares regression and intended for data trend visualization.
    Figure Legend Snippet: a , d The mean ( n = 18) pre-immunization (Pre) and highest post-vaccination (Post) frequency of antigen-specific IFN- γ + ( a ) or IL-17 + T ( d ) cell frequencies (per million PBMCs plated) that recognize the vaccine epitopes as well as the whole FRα protein. Post-vaccination samples included up to week 19. P values were calculated using the 2-sided test Wilcoxon matched pairs at a significance level of P ≤ 0.05. b , e The % of patients that responded to vaccine epitopes with IFN- γ + or IL-17 + T cell responses, respectively. c , f The distribution of IFN- γ + and IL-17 + T cell responses to the individual epitopes, respectively. g Correlation analysis heatmap comparing the magnitude of maximal peptide-specific IFN- γ + T cells to each other and to the maximal FRα protein-specific IFN- γ + T cell response. Inset values are Spearman’s Rho. h The same for IL-17 + T cell responses. All correlations ≥0.45 were P < 0.05 (Benjamini-Hochberg adjusted two-sided test, exact P values are indicated in Supplementary Tables and ). i Correlation plot between the protein-specific IFN- γ + T cell response and the IL-17 analyses between the highest FRα protein-specific IFN- γ + and highest FRα protein-specific IL-17 + T cells. j Correlation analysis between the number of peptides to which IFN- γ + T cells were generated and the number of peptides to which IL-17 + T cells were generated. k Correlation plots between the vaccine IFN- γ score (The sum of the individual patient T cell response to the epitopes) and tumor FRα expression. Inset values for ( i – k ) are Spearman’s Rho coefficient ( r ) and P value. l Correlation plots between the vaccine Th17 score (The sum of the individual patient T cell response to the epitopes) and tumor FRα expression. Inset values are Pearson’s Rho coefficient (r) and P value. Each symbol in ( i – l ) represents a unique patient ( n = 18 for each panel). In some cases the symbols overlap obscuring each other. Inset best-fit lines were calculated with non-linear least squares regression and intended for data trend visualization.

    Techniques Used: Generated, Expressing

    a – h Induction phase times courses of antigen-specific antibody levels (μg/ml, mean + s.e.m.) for FRα epitopes FR30, FR56, FR76, FR113, FR238 and FRα protein, TT, and control cyclin D1 peptide, respectively, in 18 evaluable patients. Reddened symbols indicate P < 0.008 (Bonferroni corrected) significance by Wilcoxon matched pairs two-sided test, compared to the baseline value for that antigen. Exact P values are indicated in Supplementary Table . i The mean ( n = 18) pre-immunization (Pre) and highest post-vaccination (Post) frequency of antigen-specific antibody levels (μg/ml) to the vaccine epitopes as well as the whole FRα protein. Post-vaccination samples included up to week 19. P values were calculated using the two-sided test Wilcoxon matched pairs at a significance level of P ≤ 0.05. j % of patients that responded to vaccine epitopes with antibody responses at the ≥2-fold increase threshold. k The distribution of antibody responses to the individual epitopes. l , m Levels of FRα protein-specific antibodies over the time course of the 19-week vaccine period, expressed a % of baseline, for two patients. Plasma was left either untreated (red line) or pre-absorbed (black line) with pooled vaccine peptides prior to ELISA. Each data symbol represents mean (+s.e.m.) of two replicates. P values were calculated using two-sided two-way analysis of variance. n Correlation heatmap comparing the magnitude of maximal peptide-specific antibody levels to the maximal FRα protein-specific and epitope-specific antibody levels. Inset values are Spearman’s Rho. Correlations >0.56 were P < 0.05 (Benjamini-Hochberg two-sided adjusted P values). Exact P values are indicated in Supplementary Table . o Correlation plot between the vaccine antibody score (sum of the individual patients response to each epitope) and tumor FRα expression. Inset values are Pearsons’s Rho coefficient and P value. Each symbol represents a unique patient and the inset line is best-fit lines was calculated with non-linear least squares regression and intended for data trend visualization. p , q Pre- and post-immunization (19-week time point) serum levels of IgG antibodies specific for p53 and hTERT, respectively, in each of the 18 patients. Inset blue bar represents the mean levels of antibodies for all patients at pre- and post-immunization. P values comparing the means were calculated with a two-sided paired Student’s t test.
    Figure Legend Snippet: a – h Induction phase times courses of antigen-specific antibody levels (μg/ml, mean + s.e.m.) for FRα epitopes FR30, FR56, FR76, FR113, FR238 and FRα protein, TT, and control cyclin D1 peptide, respectively, in 18 evaluable patients. Reddened symbols indicate P < 0.008 (Bonferroni corrected) significance by Wilcoxon matched pairs two-sided test, compared to the baseline value for that antigen. Exact P values are indicated in Supplementary Table . i The mean ( n = 18) pre-immunization (Pre) and highest post-vaccination (Post) frequency of antigen-specific antibody levels (μg/ml) to the vaccine epitopes as well as the whole FRα protein. Post-vaccination samples included up to week 19. P values were calculated using the two-sided test Wilcoxon matched pairs at a significance level of P ≤ 0.05. j % of patients that responded to vaccine epitopes with antibody responses at the ≥2-fold increase threshold. k The distribution of antibody responses to the individual epitopes. l , m Levels of FRα protein-specific antibodies over the time course of the 19-week vaccine period, expressed a % of baseline, for two patients. Plasma was left either untreated (red line) or pre-absorbed (black line) with pooled vaccine peptides prior to ELISA. Each data symbol represents mean (+s.e.m.) of two replicates. P values were calculated using two-sided two-way analysis of variance. n Correlation heatmap comparing the magnitude of maximal peptide-specific antibody levels to the maximal FRα protein-specific and epitope-specific antibody levels. Inset values are Spearman’s Rho. Correlations >0.56 were P < 0.05 (Benjamini-Hochberg two-sided adjusted P values). Exact P values are indicated in Supplementary Table . o Correlation plot between the vaccine antibody score (sum of the individual patients response to each epitope) and tumor FRα expression. Inset values are Pearsons’s Rho coefficient and P value. Each symbol represents a unique patient and the inset line is best-fit lines was calculated with non-linear least squares regression and intended for data trend visualization. p , q Pre- and post-immunization (19-week time point) serum levels of IgG antibodies specific for p53 and hTERT, respectively, in each of the 18 patients. Inset blue bar represents the mean levels of antibodies for all patients at pre- and post-immunization. P values comparing the means were calculated with a two-sided paired Student’s t test.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Expressing

    a The RFS and the OS from the time of study enrollment (4–20 weeks after first-line chemotherapy) for all patients eligible for efficacy analysis ( n = 18) via Kaplan–Meier analysis. b – d Compare IFN- γ , IL-17, and antibody immune response scores (sum of the mean immune responses to the epitopes), respectively, of those who recurred (blue symbols, n = 11) and those who did not recur (red symbols, n = 78). e Compares the mean (+s.e.m.) antibody levels to whole FRα protein in those that recurred and those that did not recur. P values for ( b – e ), comparing the separation of the two curves, are calculated using a two-way ANOVA test. Expanded datasets are shown in Supplementary Fig. . f – h Maintenance phase time courses of antigen-specific IFN- γ + and IL-17 + T cell frequencies (T cells per million PBMCs) or the antibody concentrations for FRα epitopes FR30, FR56, FR76, FR113, and FR238, and control cyclin D1 peptide, respectively, in eight evaluable patients. i The individual and mean (±s.e.m.) percentage of dead cells killed through ADCC assayed with post-immunization (Week 19) plasma samples from patients who did not recur ( n = 7) and did recur ( n = 11). j Bars (mean + s.e.m.) show relative levels of IgG subtypes (IgG1-4) in n = 5 patients with recurrence and n = 3 patients with no recurrence. k The pre- and post-vaccination (i.e., week 19) circulating levels of Tregs in eight evaluable patients. l – p The individual and mean (±s.e.m.) tumor Treg counts, tumor CD8 T cell counts, CD8/Treg ratio, tumor FRα, and PD-L1 expression, respectively, in the primary tumors of patients who did (Yes) and did not (No) have recurrence. q – t Compare the tumor FRα expression, CD8 T cell infiltration, Treg infiltration, and PD-L1 expression, respectively in primary and corresponding recurrent tumors from n = 5–6 patients with recurrence. P values for ( i – t ) were calculated using the two-sided paired Student’s t test. Symbols in some cases overlap obscuring the number of patients.
    Figure Legend Snippet: a The RFS and the OS from the time of study enrollment (4–20 weeks after first-line chemotherapy) for all patients eligible for efficacy analysis ( n = 18) via Kaplan–Meier analysis. b – d Compare IFN- γ , IL-17, and antibody immune response scores (sum of the mean immune responses to the epitopes), respectively, of those who recurred (blue symbols, n = 11) and those who did not recur (red symbols, n = 78). e Compares the mean (+s.e.m.) antibody levels to whole FRα protein in those that recurred and those that did not recur. P values for ( b – e ), comparing the separation of the two curves, are calculated using a two-way ANOVA test. Expanded datasets are shown in Supplementary Fig. . f – h Maintenance phase time courses of antigen-specific IFN- γ + and IL-17 + T cell frequencies (T cells per million PBMCs) or the antibody concentrations for FRα epitopes FR30, FR56, FR76, FR113, and FR238, and control cyclin D1 peptide, respectively, in eight evaluable patients. i The individual and mean (±s.e.m.) percentage of dead cells killed through ADCC assayed with post-immunization (Week 19) plasma samples from patients who did not recur ( n = 7) and did recur ( n = 11). j Bars (mean + s.e.m.) show relative levels of IgG subtypes (IgG1-4) in n = 5 patients with recurrence and n = 3 patients with no recurrence. k The pre- and post-vaccination (i.e., week 19) circulating levels of Tregs in eight evaluable patients. l – p The individual and mean (±s.e.m.) tumor Treg counts, tumor CD8 T cell counts, CD8/Treg ratio, tumor FRα, and PD-L1 expression, respectively, in the primary tumors of patients who did (Yes) and did not (No) have recurrence. q – t Compare the tumor FRα expression, CD8 T cell infiltration, Treg infiltration, and PD-L1 expression, respectively in primary and corresponding recurrent tumors from n = 5–6 patients with recurrence. P values for ( i – t ) were calculated using the two-sided paired Student’s t test. Symbols in some cases overlap obscuring the number of patients.

    Techniques Used: Expressing

    frα protein  (Sino Biological)


    Bioz Verified Symbol Sino Biological is a verified supplier
    Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Sino Biological frα protein
    Vaccine <t> FRα </t> peptides
    Frα Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/frα protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    frα protein - by Bioz Stars, 2023-03
    93/100 stars

    Images

    1) Product Images from "Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients"

    Article Title: Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    doi: 10.1158/1078-0432.CCR-17-2499

    Vaccine FRα peptides
    Figure Legend Snippet: Vaccine FRα peptides

    Techniques Used:

    Panel A shows a representative set of flow cytometry dot plots demonstrating detection of Tregs using CD4, CD25, FoxP3, and CD127. Panel B: Bars show the mean levels of Tregs in 17 evaluable patients measured on time points 0 and 1 month before and after treatment with CTX just prior to vaccination. Each line traces the pre- and post-CTX Treg levels for a single unique patient. Panel C shows the mean (n=14 patients) pre-immunization (Pre) and highest post-vaccination (Post) frequency of antigen-specific T cells frequencies (per million PBMC plated) that recognize vaccine antigens, FR30, FR56, FR76, FR113, and FR238. Also shown are frequencies to control cyclin D1 and the FRα protein. Shown are the high post-vaccination values for the vaccine period which includes measurements up to 30 days following final injection. Panel D shows the mean pre-immunization (Pre) and highest post-vaccination frequency of tetanus toxoid-specific T cells for same patients in Panel C. Panel E shows the mean pre-immunization (Pre) and highest post-vaccination (Post) frequency of antigen-specific antibodies (μg/ml) that recognize vaccine antigens, FR30, FR56, FR76, FR113, FR238, control cyclin D1 and the FRα protein. Panel F shows the mean pre-immunization (Pre) and highest post-vaccination (Post) frequency of tetanus toxoid-specific antibodies (μg/ml) for same patients in Panel C. p values shown were calculated using the paired student’s T test. For panels C-F, each line traces the pre- and post-antigen-specific T cell levels for a single unique patient measured during the vaccine period.
    Figure Legend Snippet: Panel A shows a representative set of flow cytometry dot plots demonstrating detection of Tregs using CD4, CD25, FoxP3, and CD127. Panel B: Bars show the mean levels of Tregs in 17 evaluable patients measured on time points 0 and 1 month before and after treatment with CTX just prior to vaccination. Each line traces the pre- and post-CTX Treg levels for a single unique patient. Panel C shows the mean (n=14 patients) pre-immunization (Pre) and highest post-vaccination (Post) frequency of antigen-specific T cells frequencies (per million PBMC plated) that recognize vaccine antigens, FR30, FR56, FR76, FR113, and FR238. Also shown are frequencies to control cyclin D1 and the FRα protein. Shown are the high post-vaccination values for the vaccine period which includes measurements up to 30 days following final injection. Panel D shows the mean pre-immunization (Pre) and highest post-vaccination frequency of tetanus toxoid-specific T cells for same patients in Panel C. Panel E shows the mean pre-immunization (Pre) and highest post-vaccination (Post) frequency of antigen-specific antibodies (μg/ml) that recognize vaccine antigens, FR30, FR56, FR76, FR113, FR238, control cyclin D1 and the FRα protein. Panel F shows the mean pre-immunization (Pre) and highest post-vaccination (Post) frequency of tetanus toxoid-specific antibodies (μg/ml) for same patients in Panel C. p values shown were calculated using the paired student’s T test. For panels C-F, each line traces the pre- and post-antigen-specific T cell levels for a single unique patient measured during the vaccine period.

    Techniques Used: Flow Cytometry, Injection

    Shown in Panels A-H are times courses of antigen-specific T cell frequencies (T cells per million PBMC, mean ± s.e.m.) for FR30, FR56, FR76, FR113, FR238, FRα protein, TT, and control cyclin D1 peptide, respectively, in 14 evaluable patients. Shown in Panels I-H are times courses of antigen-specific antibody frequencies (μg/ml, mean ± s.e.m.) for 21 evaluable patients. For all panels, time 0 months represents the baseline levels prior to CTX treatment. T cell frequencies were not measured at time point 1 month.
    Figure Legend Snippet: Shown in Panels A-H are times courses of antigen-specific T cell frequencies (T cells per million PBMC, mean ± s.e.m.) for FR30, FR56, FR76, FR113, FR238, FRα protein, TT, and control cyclin D1 peptide, respectively, in 14 evaluable patients. Shown in Panels I-H are times courses of antigen-specific antibody frequencies (μg/ml, mean ± s.e.m.) for 21 evaluable patients. For all panels, time 0 months represents the baseline levels prior to CTX treatment. T cell frequencies were not measured at time point 1 month.

    Techniques Used:

    Panel A shows the mean (n=16 patients) pre-immunization (Pre) and highest observation (Post) frequency of antigen-specific T cells frequencies (per million PBMC plated) that recognize vaccine antigens, FR30, FR56, FR76, FR113, and FR238. Also shown are T cell frequencies to control cyclin D1 and the FRα protein. Shown are the high post-vaccination values for the observation period which includes measurements at months 10, 13, and 18. Panel B shows the mean pre-immunization (Pre) and highest post-vaccination frequency of tetanus toxoid-specific T cells for same patients in Panel A. Panels C-J are times courses of antigen-specific T cell frequencies (T cells per million PBMC, mean ± s.e.m.) for FR30, FR56, FR76, FR113, FR238, FRα protein, TT, and control cyclin D1 peptide, respectively, in 16 evaluable patients. p values shown were calculated using the paired student’s T test. For panels A-B, each line traces the pre- and highest observation period (Post) antigen-specific T cell levels for a single unique patient measured during the vaccine period.
    Figure Legend Snippet: Panel A shows the mean (n=16 patients) pre-immunization (Pre) and highest observation (Post) frequency of antigen-specific T cells frequencies (per million PBMC plated) that recognize vaccine antigens, FR30, FR56, FR76, FR113, and FR238. Also shown are T cell frequencies to control cyclin D1 and the FRα protein. Shown are the high post-vaccination values for the observation period which includes measurements at months 10, 13, and 18. Panel B shows the mean pre-immunization (Pre) and highest post-vaccination frequency of tetanus toxoid-specific T cells for same patients in Panel A. Panels C-J are times courses of antigen-specific T cell frequencies (T cells per million PBMC, mean ± s.e.m.) for FR30, FR56, FR76, FR113, FR238, FRα protein, TT, and control cyclin D1 peptide, respectively, in 16 evaluable patients. p values shown were calculated using the paired student’s T test. For panels A-B, each line traces the pre- and highest observation period (Post) antigen-specific T cell levels for a single unique patient measured during the vaccine period.

    Techniques Used:

    fr protein  (Sino Biological)


    Bioz Verified Symbol Sino Biological is a verified supplier
    Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Sino Biological fr protein
    Fr Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fr protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    fr protein - by Bioz Stars, 2023-03
    93/100 stars

    Images

    recombinant fr  (Sino Biological)


    Bioz Verified Symbol Sino Biological is a verified supplier
    Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Sino Biological recombinant fr
    Recombinant Fr, supplied by Sino Biological, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant fr/product/Sino Biological
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant fr - by Bioz Stars, 2023-03
    96/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • frα protein  (Sino Biological)
    93
    Sino Biological frα protein
    Frα Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/frα protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    frα protein - by Bioz Stars, 2023-03
    93/100 stars
    		  Buy from Supplier
    fr protein  (Sino Biological)
    93
    Sino Biological fr protein
    Fr Protein, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fr protein/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    fr protein - by Bioz Stars, 2023-03
    93/100 stars
    		  Buy from Supplier
    recombinant fr  (Sino Biological)
    96
    Sino Biological recombinant fr
    Recombinant Fr, supplied by Sino Biological, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant fr/product/Sino Biological
    Average 96 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant fr - by Bioz Stars, 2023-03
    96/100 stars
    		  Buy from Supplier

    Image Search Results